Effectively, a recent retrospective series of KRAS-positive, advanced/metastatic NSCLC suggests an overall bad prognosis for this subgroup of patients despite the introduction of ICI in the therapeutic landscape [54]. Here, KRAS is linked to non-small cell lung carcinoma.